U.S. Food and Drug Administration Approves Orphan Drug Designation for NXC-201 as a Treatment for Multiple Myeloma
FDA Orphan Drug Designation (“ODD”) qualifies NXC-201 for:
7 years of U.S. market exclusivity after approval
Tax credits for qualified clinical testing
Waiver of the Prescription Drug User Fee (currently at almost $3 million for a...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials